Janet Woodcock
Person
FDA acting commissioner in 2016 who approved a Duchenne muscular dystrophy drug despite a negative panel vote, setting a precedent for Aducanumab's approval.
Mentioned in 1 video
FDA acting commissioner in 2016 who approved a Duchenne muscular dystrophy drug despite a negative panel vote, setting a precedent for Aducanumab's approval.
